Last reviewed · How we verify

NCT05114460

Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal

Terminated Phase 2 Results posted Last updated 18 March 2025
What this trial tests

Phase 2 trial testing Naloxone in Opioid Overdose in 2 participants. Terminated before completion.

Timeline
1 November 2021
Primary endpoint
15 October 2024
29 October 2024

Quick facts

Lead sponsorNew York State Psychiatric Institute
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposebasic science
Enrollment2
Start date1 November 2021
Primary completion15 October 2024
Estimated completion29 October 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

New York State Psychiatric Institute

Who can join

Adults 18 to 55, any sex, with Opioid Overdose. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Clinical Opiate Withdrawal Scale (COWS) Primary · 4-week trial: Peak COWS score throughout the testing session for each dose combination.

Clinical Opiate Withdrawal Scale is an 11-item, clinician-administered measure designed to quantify the severity of opioid withdrawal. The COWS evaluates the severity of the following symptoms on a scale of 0-4 or 5: resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety, or irritability, and gooseflesh. The score on the COWS ranges from 0 to 48 points with withdrawal ratings between 5-12 considered mild, 13-24 as moderate, 25-36 as moderately severe, and \>36 considered severe.

GroupValue95% CI
Naloxone 0 mg + MJ 0.0 mg2
Naloxone 0 mg + MJ 12.5 mg2
Naloxone 0 mg + MJ 25 mg4
Naloxone 4 mg + MJ 0.0 mg27
Naloxone 4 mg + MJ 12.5 mg21
Naloxone 4 mg + MJ 25 mg20

Sponsor's own description

The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana \[Delta-9-tetrahydracannabinol (THC)\] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Nanotechnology-Enhanced Naloxone and Alternative Treatments for Opioid Addiction.
    Heyns IM, Faunce AF, Mumba MN, Kumar MNVR, et al · · 2024 · cited 2× · PMID 39144549 · DOI 10.1021/acsptsci.4c00158
  2. Evidence of heterogeneity in the opioid withdrawal syndrome: Spontaneous and precipitated withdrawal.
    Martinez S, Jones JD, Dunn KE, Huhn A, et al · · 2026 · PMID 41520950 · DOI 10.1016/j.pbb.2026.174153
  3. The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.
    Jones JD, Martinez S, Arout C, Haney M, et al · · 2025 · PMID 40839512 · DOI 10.1037/pha0000796

Verify or expand the search:

Other trials of Naloxone

Trials testing the same drug.

Other recruiting trials for Opioid Overdose

Currently open trials in the same condition.

Other New York State Psychiatric Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05114460.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing